A clinical trial update for linaclotide was recorded on July 22, 2026. The study, registered as NCT03796884 and titled "Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer," is listed as Phase 2. Its current status is active but not recruiting, meaning the trial is ongoing but is no longer enrolling new participants. Linaclotide currently holds approved regulatory status for its existing indications.
This update reflects only the trial's registered status and phase, not any outcome or result. No efficacy or safety findings are included in this update. The trial's purpose, as indicated by its title, is to evaluate linaclotide in patients across colorectal cancer stages 0 through 3. Further details on the trial's design, objectives, and eventual results can be found through the official clinical trial registry listing.
Readers interested in the broader profile of linaclotide, including its approved uses, can consult the compound overview for additional context.